A syringe is a simple reciprocating pump consisting of a plunger that fits within a cylindrical tube called a barrel. The plunger can be linearly pulled and pushed along the inside of the tube, allowing the syringe to take in and expel liquid or gas through a discharge orifice at the front end of the tube; the open end of the syringe may be fitted with a hypodermic needle, a nozzle or a tubing to help direct the flow into and out of the barrel. Syringes are used in clinical medicine to administer injections, infuse intravenous therapy into the bloodstream, apply compounds such as glue or lubricant, draw/measure liquids; the word "syringe" is derived from the Greek σύριγξ. Sectors in the syringe and needle market include disposable and safety syringes, injection pens, needleless injectors, insulin pumps, specialty needles. Hypodermic syringes are used with hypodermic needles to inject liquid or gases into body tissues, or to remove from the body. Injecting of air into a blood vessel is hazardous.
The barrel of a syringe is made of plastic or glass has graduated marks indicating the volume of fluid in the syringe, is nearly always transparent. Glass syringes may be sterilized in an autoclave. However, most modern medical syringes are plastic with a rubber piston, because this type seals much better between the piston and the barrel and because they are cheap enough to dispose of after being used only once, reducing the risk of spreading blood-borne diseases. Reuse of needles and syringes has caused spread of diseases HIV and hepatitis, among intravenous drug users. Syringes are commonly reused by diabetics, as they can go through several in a day with multiple daily insulin injections, which becomes an affordability issue for many. Though the syringe and needle are only used by a single person, this practice is still unsafe as it can introduce bacteria from the skin into the bloodstream and cause serious and sometimes lethal infections. In medical settings, single-use needles and syringes reduce the risk of cross-contamination.
Medical syringes are sometimes used without a needle for orally administering liquid medicines to young children or animals, or milk to small young animals, because the dose can be measured and it is easier to squirt the medicine into the subject's mouth instead of coaxing the subject to drink out of a measuring spoon. Syringes come with a number of designs for the area; the most well known of these is the Luer lock, which twists the two together. Bodies featuring a small, plain connection are known as slip tips and are useful for when the syringe is being connected to something not featuring a screw lock mechanism. Similar to this is the catheter tip, a slip tip but longer and tapered, making it good for pushing into things where there the plastic taper can form a tight seal; these can be used for rinsing out wounds or large abscesses in veterinary use. There is an eccentric tip, where the nozzle at the end of the syringe is not in the centre of the syringe but at the side; this causes the blade attached to the syringe to lie in line with the walls of the syringe itself and they are used when the blade needs to get close to parallel with the skin.
Syringes for insulin users are designed for standard U-100 insulin. The dilution of insulin is such. Since insulin vials are 10 mL, each vial has 1000 units. Insulin syringes are made for self injections and have friendly features: shorter needles, as insulin injections are subcutaneous rather than intramuscular, finer gauge needles, for less pain, markings in insulin units to simplify drawing a measured dose of insulin. Low dead space to reduce complications caused by improper drawing order of different insulin strengths. There are needle syringes designed to reload from a built-in tank after each injection, so they can make several or many injections on a filling; these are not used much in human medicine because of the risk of cross-infection via the needle. An exception is the personal insulin autoinjector used by diabetic patients. Venom extraction syringes are different from standard syringes, because they do not puncture the wound; the most common types have a plastic nozzle, placed over the affected area, the syringe piston is pulled back, creating a vacuum that sucks out the venom.
Attempts to treat snakebites in this way are advised against, as they are ineffective and can cause additional injury. Syringes of this type are sometimes used for extracting human botfly larvae from the skin. An oral syringe is a measuring instrument used to measure doses of liquid medicine which are expressed in millilitres, they do not have threaded tips, because other device needs to be screwed onto them. The contents are squirted or sucked from the syringe directly into the mouth of the person or animal. Oral syringes are available in various sizes, from 1 -- larger; the sizes most used are 1 mL, 2.5 mL and 5 mL. A dental syringe is a used by dentists for the injection of an anesthetic, it consists of a breech-loading syringe fitted with a sealed cartridge containing anesthetic solution. The ancillary to
Type 3c (Pancreatogenic) Diabetes
Type 3c diabetes is diabetes that comes secondary to pancreatic diseases, involving the exocrine and digestive functions of the pancreas. Around 5–10% of cases of diabetes in the Western world are related to pancreatic diseases. Chronic pancreatitis is most the cause; the same complications that occur for other types of diabetics may occur for type 3c diabetics. These include retinopathy, nephropathy and cardiovascular disease. Patients with this condition are advised to follow the same risk-reduction guidelines as the other diabetics do and keep blood sugars as normal as possible to minimize any complications. There are multiple causes; some of which identified are: Pancreatic disease Pancreatic resection Chronic pancreatitis. Lacking genes in the E2F group; the condition can be managed by many factors. Avoiding toxins to the body such as alcohol and smoking reduce pancreatic inflammation. Eating a diet rich in fiber and consuming normal amounts of fat may help. Oral pancreatic enzymes may be given.
Maintaining sufficient levels of vitamin D can reduce symptoms and help manage the disease better. Medications such as insulin may be given in order to lower blood sugars. For not so high blood sugars, oral treatments in the form of a pill or capsule may be given. Diabetes mellitus Pancreatitis Exocrine pancreatic insufficiency
An insulin pen is used to inject insulin for the treatment of diabetes. Insulin is a hormone produced by the pancreas, it is composed of an insulin cartridge and a dial to measure the dose, is used with disposable pen needles to deliver the dose. It was introduced and marketed as NovoPen by the Danish company Novo Nordisk in 1985. A number of companies make insulin pens including Novo Nordisk, Eli Lilly and Biocon; these companies produce pens for most of their insulins, including NovoLog/NovoRapid, Humalog and Lantus. There are two pen systems: durable and prefilled: A durable pen uses a replaceable insulin cartridge; when the insulin cartridge is empty, the empty cartridge is disposed of and a new one is inserted in the pen. A prefilled pen is disposable; the pen comes pre-filled with insulin, when the insulin cartridge or reservoir is empty, the entire unit is discarded. Most brands of insulin are now available for use in pens, these include: NovoMix, NovoRapid and Levemir by Novo Nordisk Lantus and Apidra by Sanofi-Aventis Humulin and Humalog by Eli Lilly and Company INSUGEN and BASALOG by Biocon Insulin pens are used by over 95% of insulin-treated patients in Europe, Asia and Scandinavia with excellent results.
They are underutilized but growing in use in the United States. Insulin pens offer several significant advantages over insulin syringes: ease of handling and they are more discreet to use and easier to transport. Screw or click on a new pen needle. If necessary, prime the pen to remove any air from the needle Turn the knob on the end of the pen to the number of units needed Insert the needle into the skin Press the button on the end of the pen to deliver the dose Count to five or ten depending on dose injected Remove Remove used pen needle for disposal Insulin pens have a number of advantages: More convenient and easier to transport than traditional vial and syringe Repeatedly more accurate dosages Easier to use for those with visual or fine motor skills impairments Less injection pain It is important that proper injection sites on the body be used. A healthcare provider helps determine the best injection site for a patient. In general, recommended injection sites include the abdomen, parts of the buttocks, parts of the upper arms and thigh areas.
Unlike with the traditional syringe, two different insulins cannot be mixed by the user in an insulin pen. On the other hand, some of the newest types of insulin cannot be mixed at all. In addition, using pens and pen needles is more expensive than using the traditional vial and syringe method. Technology has not changed much since the launch of the first insulin pen over 25 years ago by Novo Nordisk. A number of independent companies have created accessories to help people using insulin pens better manage their insulin intake. – Bee by Vigilant the Diabetes Smart Tracker serves as a cap for most insulin pens and transmits insulin injection data and glucose levels via Bluetooth to smartphones and tablets. – Dukada Trio is a'smart cap' that works with Novo and Sanofi insulen pen types that provides needle light, flexgrip for better handling and show time period sinces last injection to remove doubt of missed or accidental double doses. – Frio UK offers a wallet to help keep insulin pens cool in warm temperatures, the wallets are activated by immersing in cold water and are capable of keeping insulin cool for a number of days before they require reimmersion.
– Timesulin is a'smart cap' that works with all major insulin pen types to show users how long it has been since their insulin pen injection to help avoid missed or accidental double doses. Insulin Pen Users group Insulin Pen Reviews Insulin pump Insulin syringe Insulin port Injection port Pen needles
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, with offices in 18 countries. Its products are sold in 125 countries; the company was founded in 1876 by, named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. Lilly's notable achievements include being the first company to mass-produce the polio vaccine developed by Jonas Salk, insulin, it was one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin and the first approved biosimilar insulin product in the US, Basaglar. Lilly is the largest manufacturer of psychiatric medications and produces Prozac, Dolophine and Zyprexa; the company is ranked 129th on the Fortune 500. It is ranked 221st on the Forbes Global 2000 list of the largest public companies in the world and 252nd on the Forbes list of America's Best Employers. Eli Lilly is a full member of the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations.
As of 1997, it was the largest charitable benefactor in Indiana. The company's founder was Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran of the American Civil War. Lilly served as the company president until his death in 1898. A stylized version of his signature still appears in the company's logo. In 1869, after working for drugstores in Greencastle and Indianapolis, Lilly became a partner in a Paris, drugstore with James W. Binford. Although the drugstore was profitable, Lilly was more interested in medicinal manufacturing than running a pharmacy, he began formulating plans to create a company of his own. Lilly returned to Indianapolis. Lilly opened a drug manufacturing operation called Johnston and Lilly with John F. Johnston as his partner in 1874, but dissolved the failing partnership on March 27, 1876. Lilly used his share of the assets, which amounted to an estimated $400 in merchandise and about $1,000 in cash, to open his own pharmaceutical manufacturing business in Indianapolis in May 1876.
His new business venture became Company. On May 10, 1876, Lilly opened his own laboratory in a rented, two-story brick building at 15 West Pearl Street in Indianapolis, where he began to manufacture medicinal drugs; the sign outside, above the shop's door, read: "Eli Lilly, Chemist." Lilly began his manufacturing venture with $1,400 in working capital and three employees: Albert Hall, Caroline Kruger, Lilly's fourteen-year-old son, who had quit school to work with his father as an apprentice. One of the first medicines that Lilly began to produce was quinine, a drug used to treat malaria; the result was a "ten fold" increase in sales. At the end of 1876, his first year of business, sales reached $4,470. At the end of 1877 sales reached $11,318, by 1879 they had grown to $48,000. Lilly hired his brother, James, as his first full-time salesman in 1878. James and the subsequent sales team marketed the company's drugs nationally; the company outgrew its first location on Pearl Street, where it remained from 1876 to 1878, moved to larger quarters at 36 South Meridian Street.
In 1881 Lilly purchased a complex of buildings on property at McCarty and Alabama Streets and moved the company to its new headquarters in Indianapolis's south-side industrial area. Lilly purchased additional facilities for research and production. Lilly committed himself to producing high-quality prescription drugs, in contrast to the common and ineffective patent medicines. From its facilities in Indianapolis the company manufactured and sold "ethical drugs" for use by the medical profession. Lilly's medicines included labels. Lilly's first innovation was gelatin-coating for capsules; the company's other early innovations included fruit flavorings and sugarcoated pills, which made the medicines easier to swallow. In 1881, Lilly formally incorporated the business as Eli Lilly and Company, elected a board of directors, issued stock to family members and close associates. Colonel Lilly's only son, Josiah, a pharmaceutical chemist, graduated from the Philadelphia College of Pharmacy in 1882, joined the family business as a superintendent of its laboratory after college.
J. K. became company president in 1898. In 1883 the company contracted to mix and sell Succus Alteran, its first successful product and one its best sellers; the product was marketed as a "blood purifier" and as a treatment for syphilis, some types of rheumatism, skin diseases such as eczema and psoriasis. Sales from this product provided funds for Lilly to expand its manufacturing and research facilities. By the late 1880s Colonel Lilly was one of the Indianapolis area's leading businessmen, whose company had more than one-hundred employees and had $200,000 in annual sales; as the Lilly company grew, other businesses set up operations near the plant on Indianapolis's near south side. The area developed into one of the city's major business and industrial hubs. Lilly's production, manufacturing and administrative operations in Indianapolis occupied a complex of more than two dozen buildings covering a fifteen-block area, as well as production plants along Kentucky Avenue. Around 1890
The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentration of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance; the pancreas of a person with type 2 diabetes may be producing normal or abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance; some degree of insulin resistance may be present in a person with type 1 diabetes. The main goal of diabetes management is, as far as possible, to restore carbohydrate metabolism to a normal state. To achieve this goal, individuals with an absolute deficiency of insulin require insulin replacement therapy, given through injections or an insulin pump.
Insulin resistance, in contrast, can exercise. Other goals of diabetes management are to prevent or treat the many complications that can result from the disease itself and from its treatment; the treatment goals are related to effective control of blood glucose, blood pressure and lipids, to minimize the risk of long-term consequences associated with diabetes. They are suggested in clinical practice guidelines released by various national and international diabetes agencies; the targets are: HbA1c of 6% to 7.0% Preprandial blood glucose: 3.9 to 7.2 mmol/L 2-hour postprandial blood glucose: <10 mmol/L Goals should be individualized based on: Duration of diabetes Age/life expectancy Comorbidity Known cardiovascular disease or advanced microvascular disease Hypoglycemia awarenessIn older patients, clinical practice guidelines by the American Geriatrics Society states "for frail older adults, persons with life expectancy of less than 5 years, others in whom the risks of intensive glycemic control appear to outweigh the benefits, a less stringent target such as HbA1c of 8% is appropriate".
The primary issue requiring management is that of the glucose cycle. In this, glucose in the bloodstream is made available to cells in the body. Both aspects can require management. Another issue that ties along with the glucose cycle is getting a balanced amount of the glucose to the major organs so they are not affected negatively; the main complexities stem from the nature of the feedback loop of the glucose cycle, sought to be regulated: The glucose cycle is a system, affected by two factors: entry of glucose into the bloodstream and blood levels of insulin to control its transport out of the bloodstream As a system, it is sensitive to diet and exercise It is affected by the need for user anticipation due to the complicating effects of time delays between any activity and the respective impact on the glucose system Management is intrusive, compliance is an issue, since it relies upon user lifestyle change and upon regular sampling and measuring of blood glucose levels, multiple times a day in many cases It changes as people grow and develop It is individualAs diabetes is a prime risk factor for cardiovascular disease, controlling other risk factors which may give rise to secondary conditions, as well as the diabetes itself, is one of the facets of diabetes management.
Checking cholesterol, LDL, HDL and triglyceride levels may indicate hyperlipoproteinemia, which may warrant treatment with hypolipidemic drugs. Checking the blood pressure and keeping it within strict limits protects against the retinal and cardiovascular complications of diabetes. Regular follow-up by a podiatrist or other foot health specialists is encouraged to prevent the development of diabetic foot. Annual eye exams are suggested to monitor for progression of diabetic retinopathy. Late in the 19th century, sugar in the urine was associated with diabetes. Various doctors studied the connection. Frederick Madison Allen studied diabetes in 1909–12 published a large volume, Studies Concerning Glycosuria and Diabetes, he invented. His diet was an early attempt at managing diabetes. Modern approaches to diabetes rely upon dietary and lifestyle management combined with regular ongoing blood glucose level monitoring. Diet management allows control and awareness of the types of nutrients entering the digestive system, hence allows indirectly, significant control over changes in blood glucose levels.
Blood glucose monitoring allows verification of these, closer control important since some symptoms of diabetes are not easy for the patient to notice without actual measurement. Other approaches include exercise and other lifestyle changes. In addition, a strong partnership between the patient and the primary healthcare provider – general practitioner or internist – is an essential tool in the successful management of diabetes; the primary care doctor makes the initial diagnosis of diabetes and provides the basic tools to get the patient started on a management program. Regular appointments with the primary care physician and a certified diabetes educator are some of the best things a patient can do in the early weeks after a diagnosis of diabetes. Upon the diagnosis of diabetes, the primar
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in eight countries, affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds 25% of its shares and a supermajority of its voting shares. Novo Nordisk markets pharmaceutical products and services. Key products include diabetes care devices. Novo Nordisk is involved with hemostasis management, growth hormone therapy and hormone replacement therapy; the company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. Novo Nordisk employs more than 40,000 people globally, markets its products in 180 countries; the corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among 100 Best Companies to Work For in 2010 and 72nd in 2014 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. In 1989, Novo Industri A/S and Nordisk Gentofte A/S merged to become Novo Nordisk A/S, the world's largest producer of insulin with headquarters in Bagsværd, Copenhagen. In 1994, Novo Nordisk's existing information technology units was spun out as NNIT A/S; the company was converted into a wholly owned aktieselskab in 2004 In March 2015, NNIT was floated on the NASDAQ OMX Nordic. In 2000, Novo's enzymes business, Novozymes A/S, was spun-out. In 2013, Novo acquired Xellia for $700 million. In 2015, the company announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate. In January 2018, Reuters reported that Novo had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.
However the Ablynx board rejected this offer the same day, saying that the price undervalued the business. Novo lost out to Sanofi who bid $4.8 billion. In the same year the company announced it would acquire Ziylo for around $800 million. Novo Nordisk is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox; the company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission. Novo Nordisk founded the World Diabetes foundation to save the lives of those affected by diabetes in developing countries and supported a UN resolution to fight diabetes, making diabetes the only other disease alongside HIV / AIDS to have a commitment to combat at a UN level. Diabetes treatments account for 85% of Novo Nordisk’s business.
Novo Nordisk works with doctors and patients, to develop products for self-managing diabetes conditions. The DAWN 2001 study was a global survey of the psychosocial aspects of living with diabetes, it involved over 5,000 people with diabetes and 4,000 care providers. This study was designed to identify barriers to optimal quality of life. A follow-up study completed in 2012 involved more than 15,000 people living with, or caring for, those with diabetes. In response to UK findings, a National Action Plan was developed, with a multidisciplinary steering committee, to support the delivery of individualized person-centered care in the UK; the NAP seeks to provide a holistic approach to diabetes treatment for their families. The i3-diabetes programme is a collaboration between the King's Health Partners, one of only six Academic Health Sciences Centres in England, Novo Nordisk; the programme is a five-year collaboration designed to deliver personalised care that will lead to improved outcomes for people living with diabetes, more efficient and effective ways of caring for people with diabetes.
Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign. In March 2014, Novo Nordisk announced a partnership program entitled ‘Cities Changing Diabetes,’ which entails combating urban diabetes. Partnership includes University College London and supported by Steno Diabetes Center, as well as a range of local partners including healthcare professionals, city authorities, urban planners, businesses and community leaders. A November 2014 newspaper article suggested that a recent medical research breakthrough at Harvard University could put Novo Nordisk out of business. Dr Alan Moses, the chief medical officer of Novo Nordisk, commented that the biology of diabetes is complex but that Novo Nordisk's mission is to alleviate and cure diabetes. If this new medical advance "...meant the dissolution of Novo Nordisk, that'd be fine." Novo Nordisk was researching pulmonary delivery systems for diabetic medications, in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies In September 2014 the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.
In September 2018 it was reported that the company would lay
A cannula is a tube that can be inserted into the body for the delivery or removal of fluid or for the gathering of data. In simple terms, a cannula can surround the inner or outer surfaces of a trocar needle thus extending the effective needle length by at least half the length of the original needle, it is called an intravenous cannula. Its size ranges from 14 to 24 gauge. Different-sized cannula have different colours as coded. Decannulation is the permanent removal of a cannula of a tracheostomy cannula, once a physician determines it is no longer needed for breathing. Cannulae come with a trocar inside; the trocar is a needle. Many types of cannulae exist:Intravenous cannulae are the most common in hospital use. A variety of cannulae are used to establish cardiopulmonary bypass in cardiac surgery. A nasal cannula is a piece of plastic tubing that runs under the nose and is used to administer oxygen. A venous cannula is inserted into a vein for the administration of intravenous fluids, for obtaining blood samples and for administering medicines.
An arterial cannula is inserted into an artery the radial artery, is used during major operations and in critical care areas to measure beat-to-beat blood pressure and to draw repeated blood samples. Insertion of the venous cannula is a painful procedure that can lead to stress. Use of a vapocoolant before cannulation reduces pain during the procedure, without increasing the difficulty of cannulation. Complications may arise in the vein as a result of the cannulation procedure, the four main groups of complication are: hematoma: a collection of blood, which can result from failure to puncture the vein when the cannula is inserted or when the cannula is removed. Selection of an appropriate vein and applying pressure above the insertion point on removal of the cannula may prevent this. Infiltration: when infusate enters the subcutaneous tissue instead of the vein. To prevent this, a cannula with accurate trim distances may be used, it is essential to fix the cannula in place firmly. Embolism: this can be caused by air, a thrombus, or fragment of a catheter breaking off and entering the venous system.
It can cause a Pulmonary Embolism. Air emboli can be avoided by making sure. A thromboembolism can be avoided by using a smaller cannula. Phlebitis: an inflammation of the vein resulting from mechanical or chemical irritation or from an infection. Phlebitis can be avoided by choosing the site for cannulation and by checking the type of infusate used. A nasal cannula or an oral–nasal cannula consists of a flexible tube with multiple short, open-ended branches for comfortable insertion into the nostrils and/or mouth, may be used for the delivery of a gas, a gas mixture, or to measure airflow into and out of the nose and/or mouth; the removal of a tracheotomy tube is referred to as decannulation. A cannula is used in an emergency procedure to relieve pressure and bloating in cattle and sheep with ruminal tympany, due most to their accidentally grazing wilted legume or legume-dominant pastures alfalfa and red and white clover. Cannulas are a component used in the insertion of the Verichip. Much larger cannulas are used to research about the digestive system of cows.
In aesthetic medicine, a blunt-tip cannula or microcannula is a small tube with an edge, not sharp and an extrusion port or pore near the tip, designed for atraumatic subdermal injections of fluids or gels. Depending on the size of the internal diameter, it can be used either for the injection of cosmetic wrinkle fillers like hyaluronic acid, poly-L-lactic acid, CaHA, etc. or for fat transfer. The advantage of using these is that they are less painful, have less risk of bruising, have less swelling, a better safety profile. Accidental intravascular injections are more difficult with blunt-tip microcannulas, reducing the risk of skin necrosis and embolization to the retinal artery which can result in blindness. Indeed, in May 2015, the USA issued a warning of these risks as an FDA Safety Communication on the "Unintentional Injection of Soft Tissue Filler Into Blood Vessels In the Face". In January 2012, the "Dermasculpt" microcannula was approved by the FDA for use in the United States for use with soft tissue fillers followed by the "Magic Needle", "Softfil", "TSK by Air-Tite", "Sculpt-face".
The primary structural differences between microcannulas is the distance of the extrusion port or pore from the tip, the bluntness of the tip, the flexibility of the shaft (enough flexibility to move around sensitive structures but enough rigidity for precise placement. Since microcannula tips are blunt, a Pilot or Introducer needle is required for entry through the skin and the technique is to thread the microcannula through this tiny opening. Microcannula cosmetic injection techniques have been developed on how to best place cosmetic wrinkle fillers such as the Long MicroCannula Double Cross-Hatched Fan and the Wiggle Progression techniques. In April 2016, the concept of the use of microcannula to inject more than cosmetic fillers was first published; the technique of Microcannula Injected Local Anesthesia was described on the use of microcannula to inject local anesthesia with less pain and swelling. Introduced were Accelerated Healing After Platelet-Rich Plasm